卢旺达儿童血吸虫病与土源性蠕虫病联合化疗中吡喹酮和阿苯达唑的安全性主动监测
该主动监测研究纳入卢旺达8037名5-15岁学龄儿童,在群体给药中单次联用吡喹酮和阿苯达唑,于给药后第1、2、7天主动监测不良事件。总体累积发生率为20.6%(95%CI 19.7-21.5%),给药前有临床事件者显著更高(27.5% vs 18.7%,p<0.001),绝大多数为轻度且多在3天内缓解。
要点
- 联用吡喹酮和阿苯达唑后约1/5儿童出现至少一种不良事件,多为短暂轻度至中度。
- 最常见不良事件为头痛、头晕或晕厥、恶心和腹痛。
- 女性、年龄较大、给药前有临床事件、给药前进食种类及服用≥2片吡喹酮是不良事件的显著预测因素。
核心结论
- 吡喹酮和阿苯达唑群体给药安全且耐受性良好,但约五分之一儿童出现短暂不良事件。
- 不良事件发生率在性别和年龄组间存在显著差异,建议在群体给药项目中开展药物警戒。
研究设计与样本
- 在卢旺达开展的主动安全性监测研究,共纳入8037名5-15岁学龄儿童。
- 记录基线社会人口学、病史及已有临床症状,群体给药时单次给予吡喹酮和阿苯达唑,于给药后第1、2、7天主动监测不良事件。
主要发现
- 1658名儿童共报告3196例不良事件,其中91.3%为轻度、8.4%为中度、0.3%为重度,多数在3天内缓解。
- 最常见不良事件为头痛(21%)、头晕或晕厥(15.2%)、恶心(12.8%)和腹痛(12.2%)。
- 至少发生一种不良事件的总体累积发生率为20.6%(95%CI 19.7-21.5%)。
- 给药前有临床事件儿童的累积发生率(27.5%,95%CI 25.4-29.6%)显著高于无临床事件儿童(18.7%,95%CI 17.7-19.7%,p<0.001)。
- 女性、年龄较大、给药前有临床事件、给药前进食种类及服用≥2片吡喹酮是不良事件的显著预测因素。
临床怎么用
- 在学龄儿童群体驱虫中联用吡喹酮和阿苯达唑时,应主动监测不良事件并关注女性、年龄较大及给药前有症状的儿童。
- 给药前评估儿童已有临床症状和进食情况,有助于识别不良事件高风险者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: School-based preventive chemotherapy (Deworming) with praziquantel and albendazole to control and eliminate schistosomiasis and soil-transmitted helminths as public health problems is recommended by the World Health Organization (WHO). Safety monitoring during mass drug administration (MDA) is imperative but data from sub-Saharan Africa are scarce. OBJECTIVE: The aim of this active safety surveillance study was to identify the incidence, type, severity, and risk factors for adverse events (AEs) following mass administration of praziquantel and albendazole. METHODS: Overall, 8037 school children aged 5-15 years in Rwanda were enrolled. Baseline sociodemographic, medical history and any pre-existing clinical symptoms were recorded. Participants received a single dose of praziquantel and albendazole during MDA. AEs were actively monitored on days 1, 2, and 7 post MDA. RESULTS: Overall, 3196 AEs were reported by 1658 children; 91.3%, 8.4%, and 0.3% of the AEs were mild, moderate, and severe, respectively, and most resolved within 3 days. Headache (21%), dizziness or fainting (15.2 %), nausea (12.8%) and stomach pain (12.2%) were the most common AEs. The overall cumulative incidence of experiencing at least one type of AE was 20.6% (95% confidence interval [CI] 19.7-21.5%), being significantly higher (p < 0.001) in children with pre-MDA clinical events (27.5%, 95% CI 25.4-29.6%) than those without (18.7%, 95% CI 17.7-19.7%). Females, older age, having pre-MDA events, types of food taken before MDA and taking two or more praziquantel tablets were significant predictors of AEs. CONCLUSIONS: Praziquantel and albendazole MDA is safe and well-tolerated; however, one in five children experience transient mild to moderate, and in few cases severe, AEs. The incidence of AEs varies significantly between sex and age groups. Pharmacovigilance in the MDA program is recommended for timely detection and management of AEs.
引用
- Kabatende J, Barry A, Mugisha M, et al. Safety of Praziquantel and Albendazole Coadministration for the Control and Elimination of Schistosomiasis and Soil-Transmitted Helminths Among Children in Rwanda: An Active Surveillance Study. Drug Saf. 2022. PMID: 35819751. doi:10.1007/s40264-022-01201-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。